Treating osteoporosis: economic aspects of bisphosphonate therapy

Bibliography

• OSNES EK, LOFTHUS CM, MEYER HE et al.: Consequences of hip fracture on activities of daily life and residential needs. Osteoporos. Int. (2004) 15:567-574.
   PubMed Web of Science ®Google Scholar
• JOHNELL O, KANIS JA, ODEN A et al.: Mortality after osteoporotic fractures. Osteoporos. Int. (2004) 15:38-42.
   PubMed Web of Science ®Google Scholar
• PAPAIOANNOU A, WIKTOROWICZ ME, ADACHI JD et al.: Mortality, independence in living, and re-fracture, one year following hip fracture in Canadians. J. Obstet. Gynaecol. Can. (2000) 22:591-597.
   Google Scholar
• OLEKSIK AM, EWING S, SHEN W et al.: Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos. Int. (2005) 16:861-870.
   PubMed Web of Science ®Google Scholar
• HALLBERG I, ROSENQVIST AM, KARTOUS L et al.: Health-related quality of life after osteoporotic fractures. Osteoporos. Int. (2004) 15:834-841.
   PubMed Web of Science ®Google Scholar
• JOHNELL O KANIS J: Epidemiology of osteoporotic fractures. Osteoporos. Int. (2005) 16(Suppl. 2):S3-S7.
   PubMed Web of Science ®Google Scholar
• JACKSON SA, TENENHOUSE A, ROBERTSON L: Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos. Int. (2000) 11:680-687.
   PubMed Web of Science ®Google Scholar
• RIGGS BL MELTON LJ III: The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone (1995) 17:505S-511S.
   PubMed Web of Science ®Google Scholar
• MELTON LJ, III, GABRIEL SE, CROWSON CS et al.: Cost-equivalence of different osteoporotic fractures. Osteoporos. Int. (2003) 14:383-388.
   PubMed Web of Science ®Google Scholar
• JOHNELL O KANIS JA: An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos. Int. (2004) 15:897-902.
   PubMed Web of Science ®Google Scholar
• KANIS JA, ODEN A, JOHNELL O et al.: The components of excess mortality after hip fracture. Bone (2003) 32:468-473.
   PubMed Web of Science ®Google Scholar
• FARAHMAND BY, MICHAELSSON K, AHLBOM A et al.: Survival after hip fracture. Osteoporos. Int. (2005) 16(12):1583-1590.
   PubMed Web of Science ®Google Scholar
• NIH CONSENSUS DEVELOPMENT PANEL ON OSTEOPOROSIS PREVENTION, DIAGNOSIS, AND THERAPY: Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 285:785-795.
   PubMed Web of Science ®Google Scholar
• GOEREE R, O’BRIEN B, PETTITT D et al.: An assessment of the burden of illness due to osteoporosis in Canada. J. Soc. Obstet. Gynaecol. (1996) 18:15-24.
   Google Scholar
• WIKTOROWICZ ME, GOEREE R, PAPAIOANNOU A et al.: Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos. Int. (2001) 12:271-278.
   PubMed Web of Science ®Google Scholar
• STEVENSON M, LLOYD JM, DE NIGRIS E et al.: A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol. Assess (2005) 9:1-160.
   PubMed Web of Science ®Google Scholar
• KEEN RW: Burden of osteoporosis and fractures. Curr. Osteoporos. Rep (2003) 1:66-70.
   PubMedGoogle Scholar
• REGINSTER JY: Treatment of postmenopausal osteoporosis. Br. Med. J. (2005) 330:859-860.
   PubMed Web of Science ®Google Scholar
• LAUPACIS A: Osteoporosis guidelines. CMAJ (2003) 168:1644-1645.
   Google Scholar
• Prevention and management of osteoporosis. World Health Organ. Tech. Rep. Ser (2003) 921:1-164.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, WELLS G, WILLAN A et al.: Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev. (2002) 23:508-516.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, TUGWELL P, ADACHI J et al.: Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr. Rev (2002) 23:517-523.
   PubMed Web of Science ®Google Scholar
• ADACHI JD, RIZZOLI R, BOONEN S et al.: Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clin. Exp. Res (2005) 17:150-156.
   PubMed Web of Science ®Google Scholar
• HARRINGTON JT, STE-MARIE LG, BRANDI ML et al.: Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif. Tissue Int. (2004) 74:129-135.
   PubMed Web of Science ®Google Scholar
• BAGGER YZ, TANKO LB, ALEXANDERSEN P et al.: The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: results from the Prospective Epidemiological Risk Factors study. Osteoporos. Int. (2006) 17(3):471-477.
   PubMed Web of Science ®Google Scholar
• EASTELL R, BARTON I, HANNON RA et al.: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res (2003) 18:1051-1056.
   PubMed Web of Science ®Google Scholar
• WATTS NB, GEUSENS P, BARTON IP et al.: Relationship between changes in bmd and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J. Bone Miner. Res. (2005) 20:2097-2104.
   PubMed Web of Science ®Google Scholar
• KANIS JA, JOHNELL O, DE LAET C et al.: A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 35:375-382.
   PubMed Web of Science ®Google Scholar
• RESZKA AA RODAN GA: Bisphosphonate mechanism of action. Curr. Rheumatol. Rep (2003) 5:65-74.
   PubMedGoogle Scholar
• RUSSELL RG ROGERS MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone (1999) 25:97-106.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, GUYATT G, KROLICKI N et al.: A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos. Int. (2001) 12:140-151.
   PubMed Web of Science ®Google Scholar
• BLACK DM, CUMMINGS SR, KARPF DB et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 348:1535-1541.
   PubMed Web of Science ®Google Scholar
• QUANDT SA, THOMPSON DE, SCHNEIDER DL et al.: Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin. Proc (2005) 80:343-349.
   PubMed Web of Science ®Google Scholar
• ROUX C, SEEMAN E, EASTELL R et al.: Efficacy of risedronate on clinical vertebral fractures within six months. Curr. Med. Res. Opin (2004) 20:433-439.
   PubMed Web of Science ®Google Scholar
• MCCLUNG MR, GEUSENS P, MILLER PD et al.: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med (2001) 344:333-340.
   PubMed Web of Science ®Google Scholar
• FELSENBERG D, MILLER P, ARMBRECHT G et al.: Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone (2005) 37:651-654.
   PubMed Web of Science ®Google Scholar
• BLACK DM, BILEZIKIAN JP, ENSRUD KE et al.: One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N. Engl. J. Med. (2005) 353:555-565.
   PubMed Web of Science ®Google Scholar
• EISMAN JA, RIZZOLI R, ROMAN-IVORRA J et al.: Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr. Med Res. Opin (2004) 20:699-705.
   PubMed Web of Science ®Google Scholar
• HARRIS ST, WATTS NB, LI Z et al.: Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr. Med Res. Opin (2004) 20:757-764.
   PubMed Web of Science ®Google Scholar
• BISWAS PN, WILTON LV, SHAKIR SA: Pharmacovigilance study of alendronate in England. Osteoporos. Int. (2003) 14:507-514.
   PubMed Web of Science ®Google Scholar
• BROWN JP JOSSE RG: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 167:S1-S34.
   PubMed Web of Science ®Google Scholar
• HODGSON SF, WATTS NB, BILEZIKIAN JP et al.: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr. Pract (2003) 9:544-564.
   PubMedGoogle Scholar
• ROYAL COLLEGE OF PHYSICIANS: Osteoporosis: Clinical Guidelines for Prevention and Treatment. Royal College of Physicians (1999).
   Google Scholar
• BOONEN S, BODY JJ, BOUTSEN Y et al.: Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos. Int. (2005) 16:239-254.
   PubMed Web of Science ®Google Scholar
• KANIS JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet (2002) 359:1929-1936.
   PubMed Web of Science ®Google Scholar
• SIMINOSKI K, LESLIE WD, FRAME H et al.: Recommendations for bone mineral density reporting in Canada. Can. Assoc. Radiol. J. (2005) 56:178-188.
   Google Scholar
• KANIS JA, BORGSTROM F, DE LAET C et al.: Assessment of fracture risk. Osteoporos. Int. (2005) 16:581-589.
   Google Scholar
• KANIS JA, JOHNELL O, ODEN A, DAWSON A, DE LAET C, JONSSON B: Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. (2001) 12(12):989-995.
   Google Scholar
• CRANNEY A, WALDEGGER L, GRAHAM ID et al.: Systematic assessment of the quality of osteoporosis guidelines. BMC. Musculoskelet. Disord (2002) 3:20.
   PubMedGoogle Scholar
• LEWIECKI EM, WATTS NB, MCCLUNG MR et al.: Official positions of the international society for clinical densitometry. J Clin. Endocrinol. Metab. (2004) 89:3651-3655.
   PubMed Web of Science ®Google Scholar
• US PREVENTIVE SERVICES TASK FORCE: Screening for Osteoporosis in Postmenopausal Women: Recommendations and Rationale (2002).
   Google Scholar
• KHAN AA, BROWN JP, KENDLER D et al.: The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 167:1141-1145.
   Google Scholar
• NATIONAL OSTEOPOROSIS FOUNDATION: Physician’s guide to prevention and treatment of osteoporosis (2003).
   Google Scholar
• SHIELL A, DONALDSON C, MITTON C et al.: Health economic evaluation. J. Epidemiol. Community Health (2002) 56:85-88.
   PubMed Web of Science ®Google Scholar
• JOHANNESSON M: Theory and methods of economic evaluation of health care. Kluwer Academic Publishers, Dordrecht, the Netherlands (1996).
   Google Scholar
• ALSARRAF AA FOWLER R: Health, economic evaluation, and critical care. J. Crit. Care (2005) 20:194-197.
   PubMed Web of Science ®Google Scholar
• LAUPACIS A, FEENY D, DETSKY AS et al.: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ (1992) 146:473-481.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN MC STASON WB: Foundations of cost-effectiveness analysis for health and medical practices. N. Engl. J. Med. (1977) 296:716-721.
   PubMed Web of Science ®Google Scholar
• SINGER ME APPLEGATE KE: Cost-effectiveness analysis in radiology. Radiology (2001) 219:611-620.
   Google Scholar
• NEUMANN P: Using cost-effectiveness analysis to impove health care: opportunities and barriers. Oxford University Press, New York (2005).
   Google Scholar
• GOLD MR, SIEGEL J, RUSSELL LB, WEINSTEIN MC (Eds): Cost-effectiveness in health and medicine, 1st edn. Oxford University Press, New York (1996).
   Google Scholar
• TOSTESON AN: Quality of life in the economic evaluation of osteoporosis prevention and treatment. Spine (1997) 22:58S-62S.
   Google Scholar
• PRIETO L SACRISTAN JA: Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual. Life Outcomes (2003) 1:80.
   PubMedGoogle Scholar
• TOSTESON AN, GABRIEL SE, GROVE MR et al.: Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos. Int. (2001) 12:1042-1049.
   PubMed Web of Science ®Google Scholar
• TOSTESON AN HAMMOND CS: Quality-of-life assessment in osteoporosis: health-status and preference-based measures. Pharmacoeconomics (2002) 20:289-303.
   PubMed Web of Science ®Google Scholar
• KANIS JA JONSSON B: Economic evaluation of interventions for osteoporosis. Osteoporos. Int. (2002) 13:765-767.
   PubMed Web of Science ®Google Scholar
• KANIS JA, BRAZIER JE, STEVENSON M et al.: Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol. Assess. (2002) 6:1-146.
   PubMedGoogle Scholar
• RAFTERY J: NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br. Med. J. (2001) 323:1300-1303.
   PubMed Web of Science ®Google Scholar
• UBEL PA, HIRTH RA, CHERNEW ME et al.: What is the price of life and why doesn’t it increase at the rate of inflation? Arch. Intern. Med. (2003) 163:1637-1641.
   PubMed Web of Science ®Google Scholar
• JOHNELL O, JONSSON B, JONSSON L et al.: Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics (2003) 21:305-314.
   PubMed Web of Science ®Google Scholar
• BORGSTROM F, CARLSSON A, SINTONEN H et al.: The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos. Int. (2006) 17:996-1007.
   PubMedGoogle Scholar
• KANIS JA, JOHNELL O, ODEN A et al.: Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos. Int. (2005) 16:6-14.
   PubMed Web of Science ®Google Scholar
• SCHOUSBOE JT, ENSRUD KE, NYMAN JA et al.: Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am. Geriatr. Soc (2005) 53:1697-1704.
   PubMed Web of Science ®Google Scholar
• IGLESIAS CP, TORGERSON DJ, BEARNE A et al.: The cost utility of bisphosphonate treatment in established osteoporosis. QJM (2002) 95:305-311.
   PubMedGoogle Scholar
• BRECHT JG, KRUSE HP, FELSENBERG D et al.: Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int. J. Clin. Pharmacol. Res (2003) 23:93-105.
   PubMedGoogle Scholar
• BRECHT JG, KRUSE HP, MOHRKE W et al.: Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int. J Clin. Pharmacol. Res (2004) 24:1-10.
   PubMedGoogle Scholar
• CHRISTENSEN PM, BRIXEN K, GYRD-HANSEN D et al.: Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin. Pharmacol. Toxicol. (2005) 96:387-396.
   Google Scholar
• BORGSTROM F, JOHNELL O, JONSSON B et al.: Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone (2004) 34:1064-1071.
   PubMed Web of Science ®Google Scholar
• SORNAY-RENDU E, MUNOZ F, GARNERO P et al.: Identification of Osteopenic Women at High Risk of Fracture: The OFELY Study. J. Bone Miner. Res. (2005) 20:1813-1819.
   PubMed Web of Science ®Google Scholar
• BLACK DM, STEINBUCH M, PALERMO L et al.: An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos. Int. (2001) 12:519-528.
   PubMed Web of Science ®Google Scholar
• SCHOUSBOE JT, NYMAN JA, KANE RL et al.: Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann. Intern. Med. (2005) 142:734-741.
   PubMed Web of Science ®Google Scholar
• SCHOUSBOE JT, ENSRUD KE, NYMAN JA et al.: Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos. Int. (2005) 16:1883-1893.
   Google Scholar
• MULLINS CD OHSFELDT RL: Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J. Manag. Care Pharm. (2003) 9:150-158.
   PubMedGoogle Scholar
• KANIS JA, DAWSON A, ODEN A et al.: Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos. Int. (2001) 12:356-361.
   Google Scholar
• CRANNEY A ADACHI JD: Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf. (2005) 28:721-730.
   PubMed Web of Science ®Google Scholar
• GRIMA D, BURGE R, BECKER DL et al.: Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P&T (2002) 27:448-455.
   Google Scholar
• MELTON LJ, III, JOHNELL O, LAU E et al.: Osteoporosis and the global competition for health care resources. J. Bone Miner. Res. (2004) 19:1055-1058.
   PubMed Web of Science ®Google Scholar
• LAUPACIS A: Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ (2002) 166:44-47.
   Google Scholar
• CUMMINGS SR: Foreward. Osteoporos. Int. (1998):S1-S2.
   Google Scholar
• CRANNEY A, COYLE D, WELCH V et al.: A review of economic evaluation in osteoporosis. Arthritis Care Res. (1999) 12:425-434.
   Google Scholar
• ZETHRAEUS N, BEN SEDRINE W, CAULIN F et al.: Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos. Int. (2002) 13:841-857.
   PubMed Web of Science ®Google Scholar
• FRAENKEL L, CONSTANTINESCU F, OBERTO-MEDINA M et al.: Women’s preferences for prevention of bone loss. J. Rheumatol. (2005) 32:1086-1092.
   Google Scholar
• KANIS JA, BORGSTROM F, JOHNELL O et al.: Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos. Int. (2004) 15:862-871.
   PubMed Web of Science ®Google Scholar
• CUMMINGS SR, BLACK DM, THOMPSON DE et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1998) 280:2077-2082.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, ABADIE E, DELMAS P et al.: Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos. Int. (2006) 17(1):1-7.
   PubMed Web of Science ®Google Scholar